Xencor (XNCR) Doses First Patients in Phase 2 Trial of XmAb5871 for IgG4-RD and Phase 2 Trial in SLE
Tweet Send to a Friend
Xencor, Inc. (NASDAQ: XNCR) today announced dosing the first patient in a Phase 2 trial of XmAb®5871 in patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
